Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies.

Abstract : BACKGROUND: Artemisinin resistance in Plasmodium falciparum lengthens parasite clearance half-life during artemisinin monotherapy or artemisinin-based combination therapy. Absence of in-vitro and ex-vivo correlates of artemisinin resistance hinders study of this phenotype. We aimed to assess whether an in-vitro ring-stage survival assay (RSA) can identify culture-adapted P falciparum isolates from patients with slow-clearing or fast-clearing infections, to investigate the stage-dependent susceptibility of parasites to dihydroartemisinin in the in-vitro RSA, and to assess whether an ex-vivo RSA can identify artemisinin-resistant P falciparum infections. METHODS: We culture-adapted parasites from patients with long and short parasite clearance half-lives from a study done in Pursat, Cambodia, in 2010 (registered with ClinicalTrials.gov, number NCT00341003) and used novel in-vitro survival assays to explore the stage-dependent susceptibility of slow-clearing and fast-clearing parasites to dihydroartemisinin. In 2012, we implemented the RSA in prospective parasite clearance studies in Pursat, Preah Vihear, and Ratanakiri, Cambodia (NCT01736319), to measure the ex-vivo responses of parasites from patients with malaria. Continuous variables were compared with the Mann-Whitney U test. Correlations were analysed with the Spearman correlation test. FINDINGS: In-vitro survival rates of culture-adapted parasites from 13 slow-clearing and 13 fast-clearing infections differed significantly when assays were done on 0-3 h ring-stage parasites (10*88% vs 0*23%; p=0*007). Ex-vivo survival rates significantly correlated with in-vivo parasite clearance half-lives (n=30, r=0*74, 95% CI 0*50-0*87; p<0*0001). INTERPRETATION: The in-vitro RSA of 0-3 h ring-stage parasites provides a platform for the molecular characterisation of artemisinin resistance. The ex-vivo RSA can be easily implemented where surveillance for artemisinin resistance is needed. FUNDING: Institut Pasteur du Cambodge and the Intramural Research Program, NIAID, NIH.
Complete list of metadata

Cited literature [36 references]  Display  Hide  Download

https://hal-riip.archives-ouvertes.fr/pasteur-00863935
Contributor : Didier Menard Connect in order to contact the contributor
Submitted on : Friday, December 20, 2013 - 7:00:11 AM
Last modification on : Thursday, April 7, 2022 - 10:10:20 AM
Long-term archiving on: : Thursday, March 20, 2014 - 10:05:25 PM

File

Lancet_ID_RSA_v2.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Benoit Witkowski, Chanaki Amaratunga, Nimol Khim, Sokunthea Sreng, Pheaktra Chim, et al.. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies.. The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2013, epub ahead of print. ⟨10.1016/S1473-3099(13)70252-4⟩. ⟨pasteur-00863935⟩

Share

Metrics

Record views

194

Files downloads

1029